Bulls Keep Del Fris...
Health Care: Drugs
Rexahn Pharmaceuticals Inc. (RNN: AMEX)
$0.32 0.00 | 1.56%
05/17/13 - 03:58 PM ET
368.30K / 372.20K
Vol / Avg. Vol:0.32 / 0.32
Open / Prev. Close:0.31 - 0.33
Today's Range:0.28 - 0.81
52 Wk Range:3.23%
Performance YTD:TheStreet Rating:
Portfolios with RNN
- Portfolio NameUser Type
- Uservlady 1
- ContributorStocks With Big Insider Buy...
- Userinsider buying
- Contributor6 Stocks With Big Insider B...
- Contributor6 Penny Stocks for the Biot...
- Userdec28/10
- Userw0wieet Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
- User©SUPRATRADE HOT STOCKS (...
- Usergeorge paizakis
Latest RNN Headlines from TheStreet
- Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta 08.31.12 | 07:08 am
- Insiders Trading FURX, MELI, FRP 05.23.11 | 08:05 am
- 6 Stocks With Big Insider Buying 04.12.11 | 02:04 pm
- Insiders Trading RNN, LULU, KYN, GES 04.06.11 | 09:04 am
- Biotech Mailbag: BIO CEO Wrap 02.18.11 | 07:02 am
- Biotech Stock Mailbag: Protalix BioTherapeutics 02.11.11 | 07:02 am
- Rexahn Higher on Deja Vu Stock Promotion 02.08.11 | 08:02 am
- 6 Penny Stocks for the Biotech Boom 02.01.11 | 03:02 pm
- Genoptix, Clinical Data: Small-Cap Winners 01.24.11 | 01:01 pm
- Wendy's/Arby's, BioLase: Small-Cap Winners 01.20.11 | 12:01 pm
Press Releases for RNN
- Rexahn Pharmaceuticals To Present At The 25th Annual ROTH Conference - Business Wire 03.11.13 | 08:03 am
- Rexahn Pharmaceuticals Provides Key Goals For 2013 - Business Wire 02.19.13 | 08:02 am
- Rexahn Pharmaceuticals Appoints Peter D. Suzdak As Chief Executive Officer - Business Wire 01.22.13 | 08:01 am
- Rexahn Pharmaceuticals Expands Its Intellectual Property Around Class Of Potent Anti-cancer Isoquinolinamine Compounds - Business Wire 12.17.12 | 08:12 am
- Rexahn Pharmaceuticals Closes Public Offering For $6,600,000 In Gross Proceeds - Business Wire 12.04.12 | 04:12 pm
- Rexahn Pharmaceuticals Prices Public Offering Of Stock - Business Wire 11.29.12 | 09:11 am
- Rexahn Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrant - Business Wire 11.28.12 | 04:11 pm
- Teva Pharmaceutical To Increase Ownership In Rexahn - Business Wire 11.28.12 | 08:11 am
- Rexahn Pharmaceuticals Issued US Patent For Quinoxalinyl-piperazine Compounds - Business Wire 11.21.12 | 08:11 am
- Rexahn Pharmaceuticals Granted European Patent For Novel Anti-cancer Isoquinolinamine Compounds - Business Wire 09.26.12 | 08:09 am
Partner Headlines for RNN
- Ultimate Market Recap: Samsung on an Earnings Streak, More iPad Mini Evidence - Wall St. Cheat Sheet 07.06.12 | 09:07 am
- Boston Beer Co. INTRODUCES New Summer Lager and 4 End-of-Week Hot Stocks - Wall St. Cheat Sheet 07.06.12 | 02:07 am
- Inhibitex: This Is One You Might Want To Grow With - Seeking Alpha 11.09.11 | 09:11 am
- Rexahn Is a Bargain Buy - Seeking Alpha 05.31.11 | 08:05 am
- Rexahn Pharma Reports Two-Thirds of Patients Enrolled in Key Clinical Trial - Seeking Alpha 05.06.11 | 09:05 am
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
- 5 Healthcare Stocks That Insiders Are Buying Now - Seeking Alpha 04.12.11 | 08:04 am
- Rexahn to Raise $10M in Registered Direct Offering - Benzinga 03.28.11 | 01:03 pm
- Trading Halted: Rexahn Pharmaceuticals, News Pending - Benzinga 03.28.11 | 01:03 pm
- Rexahn Should Run Again - SeekingAlpha.com 04.20.10 | 04:04 pm
